Restaurants and bars say rising costs for licensing music have become untenable, pitting them against songwriters trying to make a living. https://t.co/q9anpA18IC ...

🗞️ Trump delays tariffs, adds new rates for countries.🗞️ Metaplanet to use BTC treasury for acquisitions.🗞️ More than 40 applicants for Hong Kong's stablecoin licensing regime..@jensanasie hosts "CoinDesk Daily." 👇 https://t.co/dHvrVHAfgy ...

TORONTO, July 08, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces through its subsidiary, Huge Biopharma Australia Pty Ltd., the submission of its patented candidate breakthrough drug, Lucid-21-302 (Lucid-MS), to the Innovative Licensing and Access Pathway (ILAP) Passport program in the United Kingdom (UK). Th ...

Celebrities have long used fame to peddle things. But many are now rethinking the value of traditional endorsement and licensing deals.Instead they’re launching their own businesses https://t.co/h6h5Ck1KlJ ...

1 Forward-Looking Statements 2 • This presentation, including any oral presentation accompanying it, contains "forward-looking statements," including statements about Lexicon's strategy and operating performance and events or developments that we expect or anticipate will occur in the future, such as projections of our future results of operations or of our financial condition, the potential therapeutic and commercial potential of pilavapadin (LX9211), LX9851, sotagliflozin and our other drug programs, the ...

Core Insights - Summit Therapeutics' stock surged by 8% following a report that AstraZeneca is interested in a licensing deal, significantly outperforming the S&P 500's 0.8% increase [1][2] Group 1: Partnership Details - AstraZeneca is reportedly in discussions with Summit Therapeutics regarding a partnership focused on the investigational lung cancer treatment ivonescimab, which Summit licenses from Akeso [2][4] - The potential deal could involve an upfront payment of several billion dollars, along with milestone payments, totaling up to $15 billion [5] Group 2: Market Reaction - The interest from AstraZeneca indicates strong confidence in the drug development program, which has garnered attention due to its performance in late-stage clinical trials [4][6] - Investors reacted positively to the news, reflecting optimism about Summit's future prospects if the deal materializes [6]

LAS VEGAS, July 01, 2025 (GLOBE NEWSWIRE) -- Galaxy Gaming, Inc. (OTC: GLXZ), the world’s leading independent developer and distributor of casino table games and technology, and Hasbro, Inc. (NASDAQ:HAS), a leading games, IP and toy entertainment company, today announced they have entered into a multi-year licensing agreement through which Galaxy Gaming will bring Hasbro's iconic games to casino table game pits. Under the terms of the agreement, Galaxy Gaming will develop and distribute casino table games b ...

Singapore to 'Thread the Needle' as Crypto Licensing Rules Take Effect► https://t.co/wQ1qboPDnW https://t.co/wQ1qboPDnW ...

Hong Kong accelerates RWA tokenization, crypto licensing push in new policy statement https://t.co/593nTmxewu ...

Core Insights - Amarin's shares surged 27.3% following the announcement of an exclusive long-term licensing agreement with Recordati to commercialize its drug Vazkepa across 59 EU countries [1][6]. Licensing Agreement Details - The agreement grants Recordati exclusive rights to market Vazkepa in Europe, with Amarin receiving an upfront payment of $25 million and potential milestone payments of up to $150 million based on sales targets [4][6]. - Amarin expects to achieve approximately $70 million in cost savings over the next 12 months as part of a strategy to enhance growth and reduce operational costs [3][7]. Product and Market Context - Vazkepa is approved in the EU for treating severe hypertriglyceridemia and reducing cardiovascular event risks, similar to its approval in the U.S. under the name Vascepa [2]. - The drug is protected by patents until 2039 in the EU, which supports its market expansion efforts [3]. Financial Position and Growth Strategy - The licensing deal strengthens Amarin's cash position, with nearly $300 million in cash and no debt as of March-end [7]. - The partnership with Recordati is expected to enhance Amarin's financial strength and accelerate its path to positive cash flow through new revenue opportunities [7][8]. Industry Position - Amarin's stock has increased by 65.3% year-to-date, contrasting with a 4.2% decline in the industry [5]. - Recordati's established cardiovascular portfolio, which includes treatments for hypertension and heart failure, positions it well to expand the reach of Vazkepa [8].